ClinicalTrials.gg
CompletedNCT06104319SKYLINEUpdated Oct 27, 2026Results posted

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

A Phase 2 interventional study of GSK4532990 in Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
214th of 460
61 · median 56
Started
2024
with 28 others
Phase 2
192 of 547
15 open now
Registered
497th of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 214th largest by enrollment of the 460 interventional ones that give a count, is one of 29 that started in 2024, is one of 192 in phase 2, and was the 497th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease

Keywords

  • GSK4532990
  • Non-alcoholic steatohepatitis (NASH)
  • Non-alcoholic fatty liver disease (NAFLD)
  • Suspected NASH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 75 years of age.
  • Participant must be capable of giving signed which includes compliance with the requirements and restrictions listed for the study.
  • Participants who have proven diagnosis of NASH or suspected NASH based on defined study criteria.
  • Participants must meet predefined stable use requirements of concomitant medications based on study criteria.

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  • Cirrhosis or current unstable liver or biliary disease.
  • Other causes of liver disease including, but not limited to, alcohol-related liver disease, disorders.
  • Known weight loss of ≥5% within 3 months prior to Screening.
  • Weight reduction surgery or procedures within 2 years of Screening.
  • Any to undergoing liver .
  • Any contraindication to undergoing Magnetic Resonance Imaging or FibroScan®.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    GSK4532990 Dose 1

    Participants will receive GSK4532990 Dose 1

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 2

    Participants will receive GSK4532990 Dose 2

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 3

    Participants will receive GSK4532990 Dose 3

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 4

    Participants will receive GSK4532990 Dose 4

    Drug: GSK4532990

Interventions

06

What researchers measure

Primary outcomes

  1. Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 Protein Expression Levels

    Predicted mean percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels quantify the predicted change in HSD17B13 protein expression, calculated as a percentage relative to baseline levels. The predictions are derived from a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model utilized HSD17B13 protein concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.

    Time frame: Baseline (Day 1), At weeks 8, 12 and 28

  2. Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 mRNA Expression Levels

    Predicted mean percent change from baseline (CFB) in liver biopsy-derived HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-dose baseline quantified the alteration in HSD17B13 mRNA expression at each treatment arm and post-dose biopsy time. The prediction, along with its 95% prediction interval, was estimated using a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model leveraged HSD17B13 mRNA concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.

    Time frame: Baseline (Day 1), At weeks 8, 12 and 28

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t)

    Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.

    Time frame: Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours

  2. Maximum Observed Concentration (Cmax)

    Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.

    Time frame: Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours

  3. Percent Change From Baseline (CFB) in the Observed HSD17B13 Protein Expression Levels

    Percent change from baseline in the observed HSD17B13 protein expression levels quantified the change in HSD17B13 protein expression relative to pre-treatment baseline levels, expressed as a percentage. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.

    Time frame: Baseline (Day 1), At weeks 8, 12 and 28

  4. Percent Change From Baseline (CFB) in the Observed HSD17B13 mRNA Expression Levels

    Percent change from baseline (CFB) in the observed HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-treatment baseline levels quantified the change in HSD17B13 mRNA expression. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.

    Time frame: Baseline (Day 1), At weeks 8, 12 and 28

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
Started17151514
Safety population17151514
Hsd17b13 mrna concentration population1013913
Hsd17b13 protein concentration population1011910
Pharmacokinetic population17151514
Completed17151414
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryPredicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 Protein Expression Levels

Predicted mean percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels quantify the predicted change in HSD17B13 protein expression, calculated as a percentage relative to baseline levels. The predictions are derived from a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model utilized HSD17B13 protein concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.

Time frame:
Baseline (Day 1), At weeks 8, 12 and 28
Reported as:
Mean · Percent Change
Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 Protein Expression Levels
Percent ChangeGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
CFB to Week 8-57.27 (-64.27 to -50.00)-83.16 (-87.16 to -75.47)-86.76 (-90.13 to -79.78)-88.79 (-91.71 to -82.12)
CFB to Week 12-49.03 (-55.55 to -42.73)-80.21 (-83.96 to -75.64)-84.94 (-87.93 to -81.06)-87.64 (-90.16 to -83.98)
CFB to Week 28-26.82 (-34.44 to -18.69)-61.82 (-70.08 to -51.31)-70.02 (-76.94 to -60.66)-75.27 (-81.16 to -66.83)
PrimaryPredicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 mRNA Expression Levels

Predicted mean percent change from baseline (CFB) in liver biopsy-derived HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-dose baseline quantified the alteration in HSD17B13 mRNA expression at each treatment arm and post-dose biopsy time. The prediction, along with its 95% prediction interval, was estimated using a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model leveraged HSD17B13 mRNA concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.

Time frame:
Baseline (Day 1), At weeks 8, 12 and 28
Reported as:
Mean · Percent Change
Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 mRNA Expression Levels
Percent ChangeGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
CFB to Week 8-57.85 (-66.28 to -49.38)-87.60 (-91.39 to -80.47)-91.10 (-93.98 to -86.16)-92.95 (-95.30 to -89.19)
CFB to Week 12-49.98 (-56.74 to -43.04)-84.50 (-88.03 to -80.01)-89.07 (-91.74 to -85.56)-91.54 (-93.69 to -88.62)
CFB to Week 28-28.55 (-37.34 to -19.28)-67.07 (-75.63 to -55.61)-75.45 (-82.32 to -65.35)-80.59 (-86.22 to -71.73)
SecondaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t)

Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.

Time frame:
Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
Reported as:
Geometric mean · hours*nanograms per milliter(h*ng/mL)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t)
hours*nanograms per milliter(h*ng/mL)GSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t)518 ± 65.46530 ± 33.914800 ± 44.346400 ± 38.8
SecondaryMaximum Observed Concentration (Cmax)

Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.

Time frame:
Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax)
ng/mLGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
Maximum Observed Concentration (Cmax)43.6 ± 46.3412 ± 51.0914 ± 61.32890 ± 60.2
SecondaryPercent Change From Baseline (CFB) in the Observed HSD17B13 Protein Expression Levels

Percent change from baseline in the observed HSD17B13 protein expression levels quantified the change in HSD17B13 protein expression relative to pre-treatment baseline levels, expressed as a percentage. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.

Time frame:
Baseline (Day 1), At weeks 8, 12 and 28
Reported as:
Least squares mean · Percent change
Percent Change From Baseline (CFB) in the Observed HSD17B13 Protein Expression Levels
Percent changeGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
CFB to Week 8-57.47 (-68.47 to -46.47)-91.61 (-102.81 to -80.41)-82.20 (-94.69 to -69.71)-86.96 (-99.81 to -74.10)
CFB to Week 12-43.37 (-54.55 to -32.20)-81.78 (-91.75 to -71.81)-86.14 (-97.20 to -75.07)—
CFB to Week 28———-69.97 (-79.02 to -60.92)
SecondaryPercent Change From Baseline (CFB) in the Observed HSD17B13 mRNA Expression Levels

Percent change from baseline (CFB) in the observed HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-treatment baseline levels quantified the change in HSD17B13 mRNA expression. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.

Time frame:
Baseline (Day 1), At weeks 8, 12 and 28
Reported as:
Least squares mean · Percent change
Percent Change From Baseline (CFB) in the Observed HSD17B13 mRNA Expression Levels
Percent changeGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
CFB to Week 8-72.63 (-82.04 to -63.22)-91.83 (-101.65 to -82.02)-91.66 (-102.36 to -80.96)-90.16 (-98.13 to -82.19)
CFB to Week 12-52.18 (-61.49 to -42.87)-88.14 (-95.54 to -80.73)-91.40 (-100.83 to -81.97)—
CFB to Week 28———-80.74 (-89.39 to -72.09)

Adverse events

Collected over All cause mortality, Non-Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected upto approximately 87 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK4532990 25 Milligram (mg)0/17 (0%)1/17 (5.9%)8/17 (47.1%)
GSK4532990 200 mg0/15 (0%)0/15 (0%)5/15 (33.3%)
GSK4532990 400 mg0/15 (0%)1/15 (6.7%)5/15 (33.3%)
GSK4532990 800 mg0/14 (0%)0/14 (0%)8/14 (57.1%)
Most frequent serious events
Most frequent serious events
EventGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
Hepatic enzyme increasedInvestigations0/170/151/150/14
Chest painGeneral disorders1/170/150/150/14
Scrotal cellulitisInfections and infestations1/170/150/150/14
Most frequent other events
Showing 10 of 41
Most frequent other events
EventGSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mg
SinusitisInfections and infestations0/170/150/152/14
Upper respiratory tract infectionInfections and infestations2/170/150/151/14
NauseaGastrointestinal disorders0/170/150/151/14
AstheniaGeneral disorders0/170/150/151/14
Injection site haemorrhageGeneral disorders0/170/150/151/14
Injection site rashGeneral disorders0/170/150/151/14
Injection site reactionGeneral disorders0/170/150/151/14
Subcapsular hepatic haematomaHepatobiliary disorders0/170/150/151/14
Chronic sinusitisInfections and infestations0/170/150/151/14
Infected cystInfections and infestations0/170/150/151/14

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)GSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mgTotal
Mean50.8 ± 10.1151.9 ± 9.6850.7 ± 11.0455.4 ± 11.1352.1 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)GSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mgTotal
Female12109940
Male556521
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK4532990 25 Milligram (mg)GSK4532990 200 mgGSK4532990 400 mgGSK4532990 800 mgTotal
American Indian or Alaska Native01001
Black or African American01001
White1613151357
Unknown10012
08

Study locations

14 sites
  • GSK Investigational Site
    Chula Vista, California 91911, United States
  • GSK Investigational Site
    Montclair, California 91763, United States
  • GSK Investigational Site
    San Diego, California 91911, United States
  • GSK Investigational Site
    San Diego, California 91942, United States
  • GSK Investigational Site
    Brandon, Florida 33511, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    El Dorado, Kansas 67042, United States
  • GSK Investigational Site
    Marrero, Louisiana 70072, United States
  • GSK Investigational Site
    Austin, Texas 78745, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
  • GSK Investigational Site
    San Antonio, Texas 78240, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2025, 20 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Jan 22, 2024
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPredicted percent change from baselineMean Percent Change From Baseline (CFB) in liver biopsyLiver Biopsy-derived HSD17B13 protein expression levelsProtein Expression LevelsTime frame: Baseline (Day 1) and up to Week 28 → Baseline (Day 1), At weeks 8, 12 and 28
  • EditedPredicted percent change from baselineMean Percent Change From Baseline (CFB) in liver biopsyLiver Biopsy-derived HSD17B13 mRNA expression levelsExpression LevelsTime frame: Baseline (Day 1) and up to Week 28 → Baseline (Day 1), At weeks 8, 12 and 28
Oct 27, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedArea underUnder the concentrationConcentration-time curve from time zeroCurve From Time Zero (prePre-dose) to the last quantifiable concentrationLast Quantifiable Concentration (AUC0-t) of GSK4532990Time frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose → Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
  • EditedMaximum observed concentrationObserved Concentration (Cmax) of GSK4532990Time frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose → Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
  • EditedPercent change from baselineChange From Baseline (CFB) in the. observed Observed HSD17B13 protein expression. levelsProtein Expression LevelsTime frame: Baseline and Weeks 8, 12, or 28 post-dose → Baseline (Day 1), At weeks 8, 12 and 28
  • EditedPercent change from baselineChange From Baseline (CFB) in the. observed Observed HSD17B13 mRNA expression. levelsExpression LevelsTime frame: Baseline and Weeks 8, 12, or 28 post-dose → Baseline (Day 1), At weeks 8, 12 and 28
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPredicted percent change from baselineMean Percent Change From Baseline (CFB) in liver biopsyLiver Biopsy-derived HSD17B13 protein expression levelsProtein Expression LevelsTime frame: Baseline (Day 1) and up to Week 28 → Baseline (Day 1), At weeks 8, 12 and 28
    • EditedPredicted percent change from baselineMean Percent Change From Baseline (CFB) in liver biopsyLiver Biopsy-derived HSD17B13 mRNA expression levelsExpression LevelsTime frame: Baseline (Day 1) and up to Week 28 → Baseline (Day 1), At weeks 8, 12 and 28
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedArea underUnder the concentrationConcentration-time curve from time zeroCurve From Time Zero (prePre-dose) to the last quantifiable concentrationLast Quantifiable Concentration (AUC0-t) of GSK4532990Time frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose → Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
    • EditedMaximum observed concentrationObserved Concentration (Cmax) of GSK4532990Time frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post dose → Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
    • EditedPercent change from baselineChange From Baseline (CFB) in the. observed Observed HSD17B13 protein expression. levelsProtein Expression LevelsTime frame: Baseline and Weeks 8, 12, or 28 post-dose → Baseline (Day 1), At weeks 8, 12 and 28
    • EditedPercent change from baselineChange From Baseline (CFB) in the. observed Observed HSD17B13 mRNA expression. levelsExpression LevelsTime frame: Baseline and Weeks 8, 12, or 28 post-dose → Baseline (Day 1), At weeks 8, 12 and 28
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06104319
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Jan 22, 2024
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK4532990

Start the discussion